Skip to content
zameds

Mirtazapine (Adco-mirteron)

Mirtazapine

Adcock ingram limited

S5

Registration

Applicant
Adcock ingram limited
Certificate holder
Adcock ingram limited
Registrations
3
Schedule source
Consolidated Schedules 06 July 2026

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Adco-mirteron 15

EACH TABLET CONTAINS MIRTAZAPINE 15,0 mg

15Film-coated tabletsA390217A39/1.2/0217Approved 12 January 2026RegisteredS5PIPIL
Adco-mirteron 30

EACH TABLET CONTAINS MIRTAZAPINE 30,0 mg

30Film-coated tabletsA390218A39/1.2/0218Approved 12 January 2026RegisteredS5PIPIL
Adco-mirteron 45

EACH TABLET CONTAINS MIRTAZAPINE 45,0 mg

45Film-coated tabletsA390219A39/1.2/0219Approved 12 January 2026RegisteredS5PIPIL

Regulatory status

Where S5 sits on the scale

Prescription-only, with tighter controls on repeats.

Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S5, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.

Consolidated Schedules listings for Mirtazapine

  • S5: Mirtazapine

    Consolidated Schedules 06 July 2026, line 9570

Pharmacological class: Psychoanaleptics (antidepressants). (class 1.2)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C17H19N3265.35 g/mol

5-Methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene

Drag to rotate. Structure from PubChem CID 4205.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles